XNAS · NIKI
-8.56% · -$0.1900 · Vol Not reported
Market closed · last close 4:00 PM ET · price as of 16:00:00 ET
Niki BioSolutions, Inc. Common Stock

Niki BioSolutions, Inc. Common Stock

$2.03
Card
Relationship Map

Follow $NIKI

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $NIKI by email

Veridion Score

BETALOW CONF · 4 of 6 factors measuredMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
NIKI
Niki BioSolutions, Inc. Common Stock
Sat Oct 17 · completed session · Markets closed · resumes Mon 9:30 ET
Lowest range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

25/ 100
Veridion Score
Lowest range · LOW confidence · 4 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →or $250/yr
Cancel anytime · or Reserve · $79/moor $790/yr
Confidence: LOW · 4 of 6 factors measured · Sat Oct 17 · completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
AI Analysis
Sovereign

Why is NIKI moving today?

Sovereign unlock connects news, insider activity, analyst moves, and available price action.
About Niki BioSolutions, Inc. Common Stock
Listed since
2018
Employees
2
Country
US

Niki BioSolutions Inc, formerly Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA).

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.32
Day high
$2.40
Day low
$1.94
Previous close
$2.22
52W high
$10.17
-80.04% from high
52W low
$1.94
1% of range
Market cap
$1.7M
Beta
3.11
Shares out
814.4K
Avg volume
173.7K
VWAP
$2.22
Last session
Price history computed in-house
1W
-49.25%
1M
-56.99%
3M
-77.01%
SMA 50 $5.96 · below
SMA 200 Not reported · Not reported
52W position 1%

NIKI overview

Veridion Score
25
Registered · 2026-10-16
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around NIKI.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Public disclosures

Congress activity in NIKI

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

NIKI contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NIKI in this window.
Lobbying spend

NIKI lobbying filings, year to date.

Registered lobbying filings matched to Niki BioSolutions, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NIKI in this window.
Analyst ratings
Sovereign unlock shows available analyst consensus for NIKI.
Veridion by email

Disclosure findings, methodology notes, and product updates when we have them. No fixed schedule yet. No advertising list resale.